 Vesicular Monoamine Transport Proteins
"Vesicular Monoamine Transport Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of vesicular amine transporter proteins that catalyze the transport and storage of CATECHOLAMINES and indolamines into SECRETORY VESICLES.
| Descriptor ID |
D050493
|
| MeSH Number(s) |
D12.776.157.530.450.162.887.500.500 D12.776.157.530.562.750.500.500 D12.776.543.585.450.162.887.500.500 D12.776.543.585.562.750.500.500
|
| Concept/Terms |
Vesicular Monoamine Transport Proteins- Vesicular Monoamine Transport Proteins
- Monoamine Vesicular Transport Proteins
- Vesicular Monoamine Transporter
- Monoamine Transporter, Vesicular
- Vesicular Monoamine Transporter Proteins
- Monoamine Transporters, Vesicular
- Vesicular Monoamine Transporters
- Monoamine Vesicular Transporter
- Vesicular Transporter, Monoamine
Vesicular Monoamine Transporter 1- Vesicular Monoamine Transporter 1
- VMAT-1 Vesicular Monoamine Transporter
- VMAT 1 Vesicular Monoamine Transporter
- Chromaffin Granule Amine Transporter
|
Below are MeSH descriptors whose meaning is more general than "Vesicular Monoamine Transport Proteins".
Below are MeSH descriptors whose meaning is more specific than "Vesicular Monoamine Transport Proteins".
This graph shows the total number of publications written about "Vesicular Monoamine Transport Proteins" by people in UAMS Profiles by year, and whether "Vesicular Monoamine Transport Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 5 | 0 | 5 | | 2015 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2013 | 5 | 0 | 5 | | 2012 | 1 | 0 | 1 | | 2011 | 3 | 0 | 3 | | 2010 | 4 | 0 | 4 | | 2009 | 2 | 1 | 3 | | 2008 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vesicular Monoamine Transport Proteins" by people in Profiles over the past ten years.
-
Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. Biochem Pharmacol. 2024 10; 228:116189.
-
Zhang X, Talpos J, Berridge MS, Apana SM, Slikker W, Wang C, Paule MG. MicroPET/CT assessment of neurochemical effects in the brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol. 2021 Sep-Oct; 87:107017.
-
Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. J Pharmacol Exp Ther. 2019 11; 371(2):526-543.
-
Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J. 2018 02 09; 20(2):29.
-
Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2017 12 15; 27(24):5467-5472.
-
Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15; 795:143-149.
-
Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 09 15; 26(18):4441-4445.
-
Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 07 01; 26(13):2997-3000.
-
Joolakanti SR, Nickell JR, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 05 15; 26(10):2422-2427.
-
Freyberg Z, Sonders MS, Aguilar JI, Hiranita T, Karam CS, Flores J, Pizzo AB, Zhang Y, Farino ZJ, Chen A, Martin CA, Kopajtic TA, Fei H, Hu G, Lin YY, Mosharov EV, McCabe BD, Freyberg R, Wimalasena K, Hsin LW, Sames D, Krantz DE, Katz JL, Sulzer D, Javitch JA. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun. 2016 Feb 16; 7:10652.
-
Dutta N, Helton SG, Schwandt M, Zhu X, Momenan R, Lohoff FW. Genetic Variation in the Vesicular Monoamine Transporter 1 (VMAT1/SLC18A1) Gene and Alcohol Withdrawal Severity. Alcohol Clin Exp Res. 2016 Mar; 40(3):474-81.
-
Zhu X, Dutta N, Helton SG, Schwandt M, Yan J, Hodgkinson CA, Cortes CR, Kerich M, Hall S, Sun H, Phillips M, Momenan R, Lohoff FW. Resting-state functional connectivity and presynaptic monoamine signaling in Alcohol Dependence. Hum Brain Mapp. 2015 Dec; 36(12):4808-18.
-
Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2613-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|